HC Wainwright Reiterates “Buy” Rating for Evolus (NASDAQ:EOLS)

HC Wainwright reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $27.00 price objective on the stock. HC Wainwright also issued estimates for Evolus’ Q4 2024 earnings at $0.01 EPS, FY2026 earnings at $0.40 EPS, FY2027 earnings at $1.31 EPS and FY2028 earnings at $2.18 EPS.

EOLS has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an overweight rating on shares of Evolus in a report on Monday, September 16th. Barclays boosted their price objective on Evolus from $16.00 to $20.00 and gave the stock an overweight rating in a report on Friday, September 13th. Finally, Needham & Company LLC reiterated a buy rating and set a $22.00 target price on shares of Evolus in a research note on Friday, September 13th.

Evolus Stock Performance

EOLS opened at $16.34 on Thursday. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26. Evolus has a 12-month low of $7.44 and a 12-month high of $17.70. The business has a 50 day moving average of $15.13 and a 200-day moving average of $13.27. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -15.56 and a beta of 1.31.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analyst estimates of $65.06 million. On average, equities research analysts expect that Evolus will post -0.64 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at $1,305,643.75. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently made changes to their positions in EOLS. Quest Partners LLC acquired a new position in Evolus during the second quarter valued at approximately $43,000. Quarry LP acquired a new position in shares of Evolus during the 2nd quarter worth $54,000. Sierra Summit Advisors LLC bought a new stake in shares of Evolus during the 4th quarter worth $119,000. Profund Advisors LLC acquired a new stake in Evolus in the second quarter valued at about $130,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Evolus by 65.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,969 shares of the company’s stock valued at $154,000 after buying an additional 4,355 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.